Day: July 2, 2024

Stockholm, July 2, 2024 – Virtune, a Swedish regulated digital asset manager, is announcing the launch of Virtune XRP ETP on Nasdaq Stockholm, the largest stock exchange in the Nordic region.  About Virtune XRP ETPVirtune XRP ETP provides exposure to XRP. Like all of Virtune’s exchange-traded products, Virtune XRP ETP is 100% physically backed and fully collateralized, is denominated in SEK for the Nordic audience and is available on Avanza and Nordnet. Key Information about Virtune XRP ETP:1:1 exposure to XRP 100% physically backed 1.49% annual management feeVirtune XRP ETPFull name: Virtune XRP ETP  Short name: Virtune XRP Ticker: VIRXRP Trading currency: SEK First day of trading: Tuesday 2nd of July 2024 ISIN: SE0021486156 Stock exchange: Nasdaq StockholmAbout XRPXRP is a crypto asset designed...

Ålesund, 02.07.24, Hofseth BioCare ASA (“HBC” or the “Company”), a global leader in marine lipid and peptide research, today announces the decision to transfer its eosinophil-targeting drug candidate MA-022a to its majority-owned subsidiary HBC Immunology Inc. (“HBCI”). The patent underlying the project has been valued by KWC AS at $4.5m (based on relief-from royalty method) and HBC will therefore receive 956,813 common shares in HBCI for the transfer of the patent to HBCI.  HBC has booked approximately NOK 7.4m in costs relating to the patent as per June 1, 2024. Transfer of the patent will generate an approximately NOK 7.9m financial gain for HBC in Q2/2024 based on today’s exchange rate. Eosinophils are immune cells that become overactive in allergic and hypersensitivity conditions including allergic...

ANNOUNCEMENT NO. 270 2 July 2024 Preliminary revenue figures for the 2023/24 financial year In the fourth quarter of the 2023/24 financial year, ChemoMetec’s revenue was DKK 109.2 million, corresponding to a growth of 13.5% from the year-earlier period. The revenue for the 2023/24 financial year was DKK 407.4 million against DKK 442.3 million the previous year, corresponding to a decrease of 7.9%. The revenue in 2023/24 is thus in line with the latest disclosed guidance for the revenue of DKK 400-415 million, disclosed on 8 May 2024. In the fourth quarter of 2023/24, ChemoMetec sold XcytoMatic instruments for DKK 4.4 million, an increase of 69% compared to the third quarter of the financial year. Revenue by product groupDKKm Q4 2023/24 Q4 2022/23 Q3 2023/24 2023/24 2022/23Instruments 32.2 32.0 23.1 117.1 179.0Consumables 50.4 41.8 52.6 192.5 174.4Services 25.4 21.4 22.1 93.5 83.0Other 1.2 1.0 1.1 4.3 5.9Total...

 Nanterre, 2 July 2024 VINCI finalises acquisition of MBO GroupeMBO Groupe is a prominent French player in industrial services in general, and particularly active in the nuclear sector Its 500 employees generated €85 million in revenue in 2023 The acquisition strengthens Nuvia’s range of expertiseNuvia, VINCI Construction’s subsidiary specialised in projects and services in the nuclear sector, has finalised the acquisition of MBO Groupe, a prominent player in thermal insulation, scaffolding and confinement in France. The company is active in a variety of industrial areas, including the nuclear sector where it provides maintenance services and works on large complex new-build projects. MBO Groupe’s 500 employees at some 15 bases generated around €85 million in revenue in 2023. The acquisition strengthens Nuvia’s range of industrial...

Today, on 2 July 2024, a shareholder of AS Tallink Grupp, AKTSIASELTS INFORTAR (registry code: 10139414, “Offeror”), has notified of making a voluntary takeover offer to acquire all shares of AS Tallink Grupp not yet belonging to the Offeror with a price of EUR 0.55 per share. Below we publish the Offeror’s notice regarding the voluntary takeover offer together with the prospect annexed to it. _________________________________________________________________________________ NOTICE OF VOLUNTARY TAKEOVER OFFER TO ACQUIRE SHARES OF AKTSIASELTS TALLINK GRUPPTakeover offer and OfferorAS Infortar (company registered in Estonia with registry code 10139414 and registered address Liivalaia 9, 10118, Tallinn, Estonia, “Offeror”) in accordance with the Securities Market Act (“SMA”) and other applicable legal acts hereby makes a voluntary takeover...

Today, on 2 July 2024, a shareholder of AS Tallink Grupp, AKTSIASELTS INFORTAR (registry code: 10139414, “Offeror”), has notified of making a voluntary takeover offer to acquire all shares of AS Tallink Grupp not yet belonging to the Offeror with a price of EUR 0.55 per share. Below we publish the Offeror’s notice regarding the voluntary takeover offer together with the prospect annexed to it. _________________________________________________________________________________ NOTICE OF VOLUNTARY TAKEOVER OFFER TO ACQUIRE SHARES OF AKTSIASELTS TALLINK GRUPPTakeover offer and OfferorAS Infortar (company registered in Estonia with registry code 10139414 and registered address Liivalaia 9, 10118, Tallinn, Estonia, “Offeror”) in accordance with the Securities Market Act (“SMA”) and other applicable legal acts hereby makes a voluntary takeover...

Fingerprint Cards AB (Fingerprints™) and IN Groupe through SPS brand, leader in contactless and dual interface cards, announce the launch of its secure Component solution for contactless biometric payment cards, supporting global card manufacturers to scale up production of next-generation payment cards. In line with consumer preferences for contactless, the global biometric payment card market is anticipated to rise at a considerable rate over the coming years. To support mass global adoption, Fingerprints and IN Groupe partnered in November 2023 with the aim to simplify the manufacturing process, allowing for increased production by improving reliability and reducing costs. Through SPS brand of IN Groupe, the next-generation cards are now ready for mass global rollout. The CEO of Fingerprints, Adam Philpott, comments: “Our continuing...

PRESS RELEASE – PRIVILEGED INFORMATION  The adapted supply and commercialization conditions to better achieve the development of the first oral formulation of arsenic trioxide for the treatment of cGvHD should provide the best chances for final market access. Mont-Saint-Guibert, Belgium, July 2, 2024, 7.00am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announce the signature of global licensing, supply and commercialization agreements with Phebra Pty Ltd. related to the adaptation of the License Agreement and the MDA signed earlier in May 2021, when Phebra became a minority shareholder in Medsenic SAS. The improved terms will make it more attractive for investors to participate in the...

WISeKey Subsidiary WISeSat.Space to Bring Blockchain to Space for Improved Satellite Services Will test the node operations from the new WISeSat Satellite to be launched with SpaceX at Vandenberg Space Force Base in October this year. Geneva, Switzerland – July 2, 2024: WISeKey International Holding Ltd. (“WISeKey”) (SIX: WIHN, NASDAQ: WKEY), a global leader in cybersecurity, digital identity, and Internet of Things (IoT) innovations, today announced its subsidiary WISeSat.Space’s (“Company”) innovative project to bring blockchain technology to space, aimed at improving various aspects of the satellite industry, including logistics, insurance, government regulations, and data security. The Company expects to test operations of the blockchain nodes from the new WISeSat Satellite to be launched with SpaceX later this year. WISeSat.Space’s...

 Decision adds to existing collaboration agreement with Exelixis, permitting Ipsen to seek potential marketing authorizations for Cabometyx® (cabozantinib) in advanced pancreatic and extra pancreatic neuroendocrine tumors outside of the U.S. and Japan Agreement based on CABINET Phase III trial, led by the Alliance for Clinical Trials in Oncology, which demonstrated improvements in progression-free survival for Cabometyx versus placebo 1 Ipsen has engaged with regulatory authorities in the European Union and will submit a regulatory filing on the basis of these dataPARIS, FRANCE, 2 July 2024 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today confirmation of an expanded collaboration and license agreement with Exelixis, Inc. for the development of Cabometyx® (cabozantinib) in advanced pancreatic neuroendocrine tumors (pNETs) and...